#153356

Extracellular signal-related protein kinase 5 ERK5 Small Molecule (Collaborative Toolkit)

Please Enter Your Email ID
Email ID

Cat. #153356

Extracellular signal-related protein kinase 5 ERK5 Small Molecule (Collaborative Toolkit)

Cat. #: 153356

Sub-type: Inhibitor

Availability: Please enquire for quantities and pricing

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Steve Wedge

Tool Details
Handling
Target Details
Application Details

Tool Details

*FOR RESEARCH USE ONLY

  • Tool name: Extracellular signal-related protein kinase 5 ERK5 Small Molecule (Collaborative Toolkit)
  • Cancer: Breast cancer;Genitourinary cancer;Liver cancer
  • Cancers detailed: Breast cancer;Prostate;Hepatic
  • Tool sub type: Inhibitor
  • Primary target: ERK5
  • Description: An inhibitor of extracellular signal-related protein kinase 5 (ERK5). Mitogen/extracellular signal regulated kinase kinase-5 (MEK5) specifically activates ERK5, also known as Big MAP kinase 1 (BMK1). The MEK5/ERK5 pathway is activated by EGF and is required for EGF-induced proliferation and connexin 43 gap junction communication in certain cellular contexts. ERK5 is comprised of 815 amino acids with a unique C-terminal tail containing a myocyte enhancer factor 2 (MEF2)-interacting domain and a potent transcriptional activation domain. ERK5 regulates several transcriptional factors such as MEF2C, c-Fos, Fra-1, Sap-1, cMyc and NFÎşB. ERK5 activation has a potential role in tumorigenesis and is implicated in breast, prostate and hepatic cancer. ERK5 also plays a key role in embryogenesis; ERK5 knock-out embryos die between day 9.5 and 11.5 due to a loss of vascular integrity.
  • Purpose: Inhibitor
  • Selectivity: Tested in the DiscoveRx panel of 456 kinases at a concentration of 10 ÎźM. Seventeen kinases were inhibited by >99% at this concentration, including ERK5, and the S(35) selectivity score ((number of non-mutant kinases with % of control <35)/(number of non-mutant kinases tested)) was 0.205. Ten representative kinases were selected for Kd determinations and the three most sensitive kinases were CSF1R (46nM), DCAMKL1 (61 nM) and ERK5 (180 nM).
  • Molecular weight: A potent inhibitor of ERK5 in enzyme (IC50 = 79 nM) and whole cell (IC50 =970 nM) assays.
  • Solubility: 100ÎźM
  • Additional notes: Tested in vitro and in vivo.

Handling

  • Purity: 381 kDa

Target Details

  • Primary target: ERK5
  • Ic50: A potent inhibitor of ERK5 in enzyme (IC50 = 79 nM) and whole cell (IC50 =970 nM) assays.

Application Details

  • Application notes: Tested in vitro and in vivo. Cell permeability: Caco2 Papp A2B/B2A (Efflux ratio) = 27/26 (0.94)